9: Pituitary disease in adults

Medical Journal of Australia

Volumn 180, Issue 8, 2004, Pages 419-425

  Hurley, David M ^a   Ho, Ken K Y ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CORTISONE ACETATE; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; GLUCOCORTICOID; GONADOTROPIN; HYDROCORTISONE; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; METHYLDOPA; METOCLOPRAMIDE; OCTREOTIDE; OPIATE; PHENOTHIAZINE DERIVATIVE; PREDNISOLONE; RECOMBINANT GROWTH HORMONE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TESTOSTERONE ESTER; TETRACOSACTIDE; THYROTROPIN; THYROXINE; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE; VERAPAMIL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SOMATOMEDIN C;

ACROMEGALY; ADRENAL DISEASE; ARTICLE; AUTOPSY; BODY FAT; CLINICAL FEATURE; CORTICOTROPIN DEFICIENCY; CUSHING DISEASE; CUSHING SYNDROME; DIABETES INSIPIDUS; DRUG EFFICACY; ECTOPIC CORTICOTROPIN PRODUCTION; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPITUITARISM; HYPOTHYROIDISM; MUSCLE MASS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTINOMA; QUALITY OF LIFE; THYROTROPIN BLOOD LEVEL; TRANSSPHENOIDAL SURGERY; ADULT; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HYPOPHYSIS TUMOR; REVIEW;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CUSHING SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; OCTREOTIDE; PITUITARY DISEASES; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 3042583120     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06000.x     Document Type: Article

References (25)

1. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenoma of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981; 304: 156-158.
2. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: accult adenomas in the general population. Ann Intern Med 1994; 120: 817-820.
3. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome. Clin Endocrinol 1992; 37: 387-397.
4. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382-395.
5. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinal Metab 1998; 83:379-381.
6. Hoffman DM, O'Sullivan AJ, Baxter RC, HO KKY. Diagnosis of growth hormone deficiency in adults. Lancet 1994; 343: 1064-1068.
7. Grunstein RR, Ho KKY, Sullivan CE. Effect of somatostatin analog (octreotide) on sleep apnea in acromegaly. Ann Intern Med 1994; 121: 478-483.
8. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41:95-102.
9. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-529.
10. Orme SM, McNally RI, Cartwright RA, Belchez PE. Mortality and cancer indidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998; 83: 2730-2734.
11. Lamberts SWJ. Octreotide. N Engl J Med 1996;334:246-254.
12. Burt MG, Ho KKY. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly. Endocrine 2003; 20: 299-305.
13. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171-1171.
14. Feldkamp J, Santen R, Harms E, et al. Incidentally discovered pituitary lessions: high frequency of macroadenomas and hormone secreting adenomas - results of a prospective study. Clin Endocrinol 1999; 51: 109-113.
15. Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995; 155: 181-183.
16. Reincke M, Allolio B, Saeger W, et al. The incidentaloma of the pituitary gland. Is neurosurgery required? JAMA 1990; 264: 2772-2996.
17. Fahle-Wilson MN, Ahlquist JA. Hyperprolactinaemia due to macroprolactins: some progress but still a problem. Clin Endocrinal 2003; 58: 683-685.
18. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-909.
19. Ferrari CI, Abstract R, Bevan JS, et al. Treatment of macroprolactinoma by cabergoline: a study of 85 patients. Clin Endocrinol 1997; 46: 409-413.
20. Molich ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999; 28: 143-169.
21. Molich ME, Thorner MO, Wilson C. Therapeutic controversy: management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
22. Orth DN. Medical progress: Cushing's syndrome. N Engl J Med 1995; 332: 791-803.
23. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushingoid states. Endocr Rev 1998; 19: 647-672.
24. Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushingoid states. JAMA 1993; 269: 2232-2238.
25. Utiger RD. Treatment, and retreatment, of Cushing's disease. N Engl J Med 1997; 336: 215-217.